InSilico Medicine Cayman (HKG:3696) completed first-in-human dosing in a phase 1 clinical trial of ISM8969, according to a Wednesday Hong Kong bourse filing.
The oral NLRP3 inhibitor is being developed to treat chronic neuroinflammation and central nervous system disorders, including Parkinson's disease.
The milestone marks the first clinical achievement under the company's co-development collaboration with Hygtia Therapeutics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.